Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2007-03-19
2009-10-06
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C514S885000
Reexamination Certificate
active
07597906
ABSTRACT:
Synthetic and semisythetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger and apoptosis-like mechanism in the patient.
REFERENCES:
patent: 4595680 (1986-06-01), Della Valle et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5770234 (1998-06-01), Gristina et al.
patent: 5948756 (1999-09-01), Barenholz et al.
patent: 6290987 (2001-09-01), Modi
patent: 6312719 (2001-11-01), Hope et al.
patent: 6630313 (2003-10-01), Fadok et al.
patent: 2002/0044924 (2002-04-01), Bolton et al.
patent: 2005/0147660 (2005-07-01), Bolton et al.
patent: 2007/0087010 (2007-04-01), Bolton et al.
patent: 2008/0124386 (2008-05-01), Bolton et al.
patent: 2008/0131416 (2008-06-01), Bolton et al.
patent: 2063039 (1992-09-01), None
patent: 41 17 629 (1992-12-01), None
patent: 0 315 349 (1989-05-01), None
patent: 0 505 817 (1992-09-01), None
patent: WO 92/02226 (1992-02-01), None
patent: WO 95/23592 (1995-09-01), None
patent: WO 01/43750 (2001-06-01), None
patent: WO 01/66875 (2001-09-01), None
Aramaki, et al. “Liposomes as Immunomodulator—Inhibitory Effect of Liposomes on NO Production from Macrophases”Biol. Pharm. Bull., 2000 pp. 1267-1274, vol. 23, No. 11.
Bennett et al. “Binding and Phagocytosis of Apoptotic Vascular Smooth Muscle Cells Is Mediated in Part by Exposure of Phosphatidyserine”Circulation Research, 1995, pp. 1136-1142, vol. 77, n o. 6.
Bliss et al. “A synapic model of memory: long-term potentiation in the hippocampus”Nature1993, pp. 31-39, vol. 361.
Daemen et al. “Different Intrapepatic Distribution of Phosphatidylglycerol and Phosphatidylserine Liposomes in the Rat”Hepatology, 1997, pp. 416-423, vol. 26, No. 2.
Delwaide et al. “Double-blind randomized controlled study of phosphatidylserine in senile demented patients”Acta neurol. Scand. 1986, pp. 136-140, vol. 73.
Emoto et al. “Short Note—Exposure of Phosphatidylethanolamine on the Surface of Apoptotic Cells”Experimental Cell Research1997, pp. 430-434, vol. 232.
Fadok et al. “Macrophages That Have Ingested Apoptotic Cells In Vitro Inhibit Proinflammatory Cytokine Production Through Autocrine/Paracrine Mechanisms Involving TGF-β, PGE2, and PAF”J. Clin. Invest. 1998 pp. 890-898, vol. 101, No. 4.
Fadok et al. “Exposure fo Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages”The Journal of Immunology1992, pp. 2207-2216, vol. 148, No. 7.
Fdok et al. “A receptor for phosphatidylserine-specific clearance of apoptotic cells”Nature2000, pp. 85-90, vol. 405.
Fadok et al. “Loss of Phospholipid Asymmetry and Surface Exposure of Phosphatidylserine Is Required for Phagocytosis of Apoptotic Cells by Macrophages and Fibroblasts”The Journal of Biological Chemistry2001, pp. 1071-1077, vol. 276, No. 2.
Griffin et al. “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer disease”Proc. Natl. Acad. Sci. 1989, pp. 7611-7615, vol. 86.
Kerr et al. “Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics”Br. J. Cancer, 1972, pp. 239-257, vol. 26.
Kornbluth et al. “The immunological potential of apoptotic debris produced by tumor cells and during HIV infection”Immunology Letters, 1994, pp. 125-132, vol. 43.
Mogi et al. “Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease”Neuroscience Letters1996, pp. 13-16, vol. 211.
Monastra et al. “Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination”Neurology1993, pp. 153-163, vol. 43.
Murray et al. “Evidence That Increased Hippocampal Expression of the Cytokine Interleukin-1β Is a Common Trigger for Age—and Stress-Induced Impairments in Long-term Potentiation”The Journal of Neuroscience1998, pp. 2974-2981, vol. 18, No. 8.
Miyamoto et al. “Effects of Differently Composed Liposomes on Pulmonary Arterial Pressure in Sheep —Involvement of Pulmonary Intravascular Macrophages”Nihon Kyobu Skikkan Gakkai Zasshi1991, pp. 1268-1274 [English language abstract].
Nassander et al. “Liposomes”Biodegradable Polymers as drug Delivery Systems(M. Chasin and R. Langer, eds.) Marcel Dekker Inc., New York, NY 1990, pp. 261-338, Chapter 8.
Palatini et al. “Pharmacokinetic characterization of phosphatidylserine liposomes in the rat”Br. J. Pharmacol. 1991, pp. 345-350, vol. 102.
Shiratsuchi et al. “Phosphatidylserine-Mediated Phagocytosis of anticancer Drug-Treated Cells by Macrophages”J. Biochem. 1999, pp. 1101-1106, vol. 26, No. 6.
Zanotti et al. “Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats”Psychopharmacology1989, pp. 316-321, vol. 99.
Aramaki et al. “Inhibitory Effects of negatively Charged Liposomes on Nitric Oxide Production from Macrophages Stimulated by LPS”Biochemical Piophysical Research Communications, 1996, pp. 1-6, vol. 220.
Bruni et al. “Pharmacological effects of phosphatidylserine liposomes”Nature260:331-333 (1976).
Cenacchi et al. “Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration”Aging Clin. Exp. Res. 5:123-133 (1993).
Engel et al. “Double-blind cross-over study of phosphatidylserine vs. placebo in patients wit early dementia of the Alzheimer type”Eur. Neuropsychopharmacology2:149-155 (1992).
Miller, et al. “Is variant angina the coronary manifestation of a generalized vasospastic disorder?”The New England Journal of Medicine304(13)763-766 (1981).
Oussoren et al. “Lymphatic uptake and boidistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose”Biochimica et Biophysica Acta. 1328:261-272 (1997).
Scott, et al. “Phagocytosis and clearance of apoptotic cells is mediated by MER”Nature411:207-211 (2001).
Van Noort et al. “International Review of Cytology”, 1998.
Girolomoni et al. (1993) “Phosphatidylserine Enhances the Ability of Epidermal Langerhans Cells to Induce Contact Hypersensitivity”The Journal of Immunology150:4236-4243.
Bolton Anthony E.
Mandel Arkady
Belyavskyi Michail A
Foley & Lardner LLP
Vasogen Ireland Limited
LandOfFree
Apoptosis-mimicking synthetic entities and use thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apoptosis-mimicking synthetic entities and use thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptosis-mimicking synthetic entities and use thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077228